Global Dengue Vaccine Market 2017-2021

デング熱ワクチンの世界市場2017-2021

◆タイトル:Global Dengue Vaccine Market 2017-2021
◆商品コード:IRTNTR15495
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年11月27日
◆ページ数:78
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、デング熱ワクチンの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、デング熱ワクチンの世界市場規模及び予測、需要先別分析、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社はデング熱ワクチンの世界市場が2017-2021年期間中に年平均15.05%成長すると予測しています。当レポート上に記載されている主な企業は、GlaxoSmithKline、Merck Sharp & Dohme、Sanofi、Takeda Pharmaceuticals等です。

About Dengue Vaccine
The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking. The scientific community hypothesizes that the DENV evolved in nonhuman primates from where it spread to humans first in Southeast Asia and Africa and then to other parts of the world.

Technavio’s analysts forecast the global dengue vaccine market to grow at a CAGR of 15.05% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global dengue vaccine market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Dengue Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Merck Sharp & Dohme
• Sanofi
• Takeda Pharmaceuticals

[Other prominent vendors]
• GeneOne Life Sciences
• Medigen Biologics
• Panacea Biotec
• Sun Pharmaceutical

[Market driver]
• Rapid growth in disease prevalence
• For a full, detailed list, view our report

[Market challenge]
• Regulatory hurdles in vaccine penetration
• For a full, detailed list, view our report

[Market trend]
• Licensing deals
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market overview
• Market size and forecast

PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE ANALYSIS

PART 08: MARKET SEGMENTATION BY END-USER
• Government institutions
• Hospitals
• NGOs

PART 09: MARKET SEGMENTATION BY VACCINE TYPE
• Live attenuated vaccines
• Inactivated vaccines

PART 10: REGIONAL LANDSCAPE
• Regional comparison
• Dengue vaccine market in Americas
• Dengue vaccine market in EMEA
• Dengue vaccine market in APAC
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 13: MARKET TRENDS
• Licensing deals
• Growing awareness
• Advances in diagnostic techniques
• Novel approach to eliminate dengue

PART 14: VENDOR LANDSCAPE

PART 15: KEY VENDOR ANALYSIS
• GlaxoSmithKline
• Merck Sharp & Dohme
• Sanofi Pasteur
• Takeda Pharmaceuticals
• Other prominent vendors

PART 16: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Forms of dengue
Exhibit 02: Transmission cycle of dengue infection
Exhibit 03: Global dengue vaccine market: Snapshot
Exhibit 04: Global dengue vaccine market: Segmentation
Exhibit 05: Global dengue vaccine market 2016-2021 ($ millions)
Exhibit 06: Global dengue vaccine market: Opportunity analysis
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline landscape by development phase
Exhibit 09: Key clinical trials
Exhibit 10: Global dengue vaccine market share by end-user 2016
Exhibit 11: Global dengue vaccine market share by end-user 2021
Exhibit 12: Global dengue vaccine market by government institutions 2016-2021 ($ millions)
Exhibit 13: Global dengue vaccine market by hospitals 2016-2021 ($ millions)
Exhibit 14: Global dengue vaccine market by NGOs 2016-2021 ($ millions)
Exhibit 15: Types of dengue vaccine
Exhibit 16: Licensing of TV003 and TV005 by NIAID
Exhibit 17: Global dengue vaccine market by region 2016-2021
Exhibit 18: Regional comparison
Exhibit 19: Dengue vaccine market in Americas 2016-2021 ($ millions)
Exhibit 20: Dengue vaccine market in Americas: Year over year growth
Exhibit 21: Dengue vaccine market in EMEA 2016-2021 ($ millions)
Exhibit 22: Dengue vaccine market in EMEA: Year over year growth
Exhibit 23: Dengue vaccine market in APAC 2016-2021 ($ millions)
Exhibit 24: Dengue vaccine market in APAC: Year over year growth
Exhibit 25: Vaccines in global dengue vaccine market
Exhibit 26: GlaxoSmithKline: Key highlights
Exhibit 27: GlaxoSmithKline: Strength assessment
Exhibit 28: GlaxoSmithKline: Strategy assessment
Exhibit 29: GlaxoSmithKline: Opportunity assessment
Exhibit 30: Merck Sharp & Dohme: Key highlights
Exhibit 31: Merck Sharp & Dohme: Strength assessment
Exhibit 32: Merck Sharp & Dohme: Strategy assessment
Exhibit 33: Merck Sharp & Dohme: Opportunity assessment
Exhibit 34: Sanofi Pasteur: Key highlights
Exhibit 35: Sanofi Pasteur: Strength assessment
Exhibit 36: Sanofi Pasteur: Strategy assessment
Exhibit 37: Sanofi Pasteur: Opportunity assessment
Exhibit 38: Takeda Pharmaceuticals: Key highlights
Exhibit 39: Takeda Pharmaceuticals: Strength assessment
Exhibit 40: Takeda Pharmaceuticals: Strategy assessment
Exhibit 41: Takeda Pharmaceuticals: Opportunity assessment



【掲載企業】

GlaxoSmithKline, Merck Sharp & Dohme, Sanofi, and Takeda Pharmaceuticals, GeneOne Life Sciences, Medigen Biologics, Panacea Biotec, and Sun Pharmaceutical.

★調査レポート[デング熱ワクチンの世界市場2017-2021] (Global Dengue Vaccine Market 2017-2021 / IRTNTR15495)販売に関する免責事項
[デング熱ワクチンの世界市場2017-2021] (Global Dengue Vaccine Market 2017-2021 / IRTNTR15495)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆